ARCHIVES

NCCTG Plans To Conduct Phase II Study Of Brostallicin Plus Cisplatin For mTNBC

This article is from The Cancer Letter archive.

Vol. 33 No. 4 | April 30, 2010

Download PDF Visit The Full Archive

Related Articles

Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy

June 28, 2013

As Sequestration Hits: Varmus on Living in “Pretty Awful Times”

June 26, 2013

Data Falsification Charge To Be Aired

June 27, 1980

Capitol Hill: With money tight, support for 2015 goal is symbolic.

October 14, 2005

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001

Bross Claims New Figures Show High Radiation Risk

February 23, 1979